(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of 26.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Ptc Therapeutics's revenue in 2026 is $827,110,000.On average, 16 Wall Street analysts forecast PTCT's revenue for 2026 to be $101,198,192,360, with the lowest PTCT revenue forecast at $88,672,842,322, and the highest PTCT revenue forecast at $119,364,097,382. On average, 16 Wall Street analysts forecast PTCT's revenue for 2027 to be $117,124,465,256, with the lowest PTCT revenue forecast at $93,400,954,588, and the highest PTCT revenue forecast at $167,640,612,098.
In 2028, PTCT is forecast to generate $140,847,975,924 in revenue, with the lowest revenue forecast at $105,843,355,288 and the highest revenue forecast at $204,967,814,198.